Cancer is emerging as a major public health challenge globally. Recently, IARC
(International Association of Research on Cancer) published global cancer burden using …

Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

Importance Immunotherapy checkpoint inhibitors have generated considerable interest
because of durable responses in a number of hitherto intractable tumor types. Objective To …

Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown
to model clinical response to cancer therapy. However, it remains challenging to use these …

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan …

We generated ex vivo drug-response and multiomics profiling data for a prospective series
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Motivation Historically, gene expression has been shown to be the most informative data for
drug response prediction. Recent evidence suggests that integrating additional omics can …